Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 0.98 |
| ▸ | FLT1 | P17948 | 16/20 | 0.98 |
| ▸ | KDR | P35968 | 16/20 | 0.98 |
| ▸ | EGFR | P00533 | 14/20 | 0.98 |
| ▸ | FLT4 | P35916 | 12/20 | 0.98 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.69 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27218199 | 0.99 | FGFR1 (1.00) | FGFR1FLT1KDREGFRFLT4 | |
| Hydrochloric Acid SCHEMBL1467744 | 0.98 | FGFR1 (0.98) | FGFR1FLT1KDREGFRFLT4 | |
| SCHEMBL1467348 | 0.96 | FLT1 (1.00) | FGFR1FLT1KDREGFRFLT4 | |
| SCHEMBL1467339 | 0.94 | FLT1 (0.90) | FGFR1FLT1KDREGFRFLT4 | |
| SCHEMBL7867152 | 0.94 | KDR (0.98) | FGFR1FLT1KDREGFRFLT4 | |
| Hydrochloric Acid SCHEMBL1468342 | 0.93 | FLT1 (0.89) | FGFR1FLT1KDREGFRFLT4 | |
| Hydrochloric Acid SCHEMBL7864665 | 0.93 | KDR (1.00) | FGFR1FLT1KDREGFRFLT4 | |
| SCHEMBL7857964 | 0.92 | KDR (1.00) | FGFR1FLT1KDREGFRFLT4 | |
| Hydrochloric Acid SCHEMBL7870593 | 0.92 | KDR (0.98) | FGFR1FLT1KDREGFRFLT4 | |
| SCHEMBL17520359 | 0.90 | KDR (0.87) | FGFR1FLT1KDREGFRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181554-B1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3181554-B1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| EP-3181554-A1 | QUINAZOLINE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016023330-A1 | QUINAZOLINE DERIVATIVE | 石药集团中奇制药技术（石家庄）有限公司 | 2016-02-18 | — | — | WO | disclosed |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED | 2004-12-02 | — | — | US | disclosed |
| US-6673803-B2 | FOR TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS; ACTIVITY AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | ZENECA LIMITED (GB) | 2004-01-06 | — | — | US | disclosed |
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED | 2002-11-21 | — | — | US | disclosed |
| EP-0929530-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2002-11-20 | — | — | EP | disclosed |
| US-6414148-B1 | PRODUCE ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT IN WARM-BLOODED ANIMALS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774079-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | FGFR1 4724/4885FLT1 4472/4885KDR 3669/4885 |
| US-10421754-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | FGFR1 4724/4885FLT1 4472/4885KDR 3669/4885 |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | FGFR1 4724/4885FLT1 4472/4885KDR 3669/4885 |
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, FLT1, NR5A1 | FGFR1 177/4885FLT1 2/4885KDR 6/4885 |
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, FLT1, VEGFA | FGFR1 195/4885FLT1 2/4885KDR 4/4885 |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NR5A1, NR5A2, CNKSR1 | FGFR1 146/4885FLT1 8/4885KDR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.